Trial Profile
An Open-Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Telmisartan/hydrochlorothiazide (Primary) ; Antihypertensives
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 30 Aug 2007 Status change from in progress to completed.
- 15 Nov 2006 New trial record.